36 studies found for:    " July 01, 2009":" July 31, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Unknown  Anal HPV Infection and Abnormal Cytology in HIV-infected Women
Conditions: Cervical Cancer Screening;   HIV Infections
Intervention:
22 Unknown  Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)
Condition: HIV Infections
Intervention: Drug: Adaptavir (monomeric DAPTA)
23 Unknown  Patient Preference, Sleep Quality, and Anxiety/Depression: A Comparison of Raltegravir and Efavirenz
Conditions: Sleep Disorders;   HIV Infections
Interventions: Drug: Raltegravir for the first 2 weeks;   Drug: Efavirenz for the last 2 weeks;   Drug: Efavirenz for the first 2 weeks;   Drug: Raltegravir for the last 2 weeks
24 Recruiting Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Conditions: HIV Infection;   Pulmonary TB
Intervention: Drug: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
25 Completed
Has Results
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
Conditions: HIV Infections;   Hepatitis C;   HCV Infection
Interventions: Drug: PegIFN-2b;   Drug: RBV;   Drug: Placebo to Boceprevir;   Drug: Boceprevir
26 Completed Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Drug: efavirenz/emtricitabin/tenofovir;   Drug: lopinavir/ritonavir
27 Unknown  Simplification From Protease Inhibitors to Raltegravir
Condition: HIV Infections
Intervention: Drug: Raltegravir (Use RAL as a simplification strategy)
28 Completed Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761;   Drug: Lopinavir/ritonavir;   Drug: HAART;   Drug: Placebo
29 Active, not recruiting
Has Results
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: efavirenz
30 Active, not recruiting
Has Results
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572 (Cohort I);   Drug: GSK1349572 (Cohort II)
31 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
32 Completed
Has Results
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
Condition: HIV Infections
Interventions: Drug: raltegravir;   Drug: 2N(t)RTI;   Drug: Ritonavir-boosted lopinavir
33 Completed Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers
Conditions: HIV;   Asthma
Interventions: Drug: Darunavir;   Drug: Ritonavir;   Drug: Beclomethasone Dipropionate HFA
34 Completed
Has Results
Evaluation of Diagnostic HIV Ag/Ab Combo Assay
Condition: Human Immunodeficiency Viruses
Intervention: Device: ARCHITECT HIV Ag/Ab Combo
35 Completed GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study
Condition: Healthy Volunteer
Interventions: Drug: GSK1349572;   Drug: Placebo;   Drug: Omeprazole
36 Completed The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects
Condition: Healthy Volunteers
Interventions: Drug: Lersivirine;   Drug: Placebo;   Drug: Lersivirine (if necessary);   Drug: Moxifloxacin

Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page
Indicates status has not been verified in more than two years